NCT00473824View on ClinicalTrials.gov

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Sequelae of Viral HepatitisTransplantation InfectionEvidence of Liver Transplantation
Interventions
BIOLOGICAL

Hepatitis C Immune Globulin Intravenous (Human) 5%

Hepatitis C Immune Globulin Intravenous (Human) 5%, \[Civacir\]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.

Trial Locations (3)

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

85054

Mayo Clinic, Phoenix

Sponsors
All Listed Sponsors
lead

ADMA Biologics, Inc.

INDUSTRY